Cardiol Retained Earnings vs Other Stockholder Equity Analysis
CRDL Stock | USD 1.36 0.07 4.90% |
Cardiol Therapeutics financial indicator trend analysis is way more than just evaluating Cardiol Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiol Therapeutics is a good investment. Please check the relationship between Cardiol Therapeutics Retained Earnings and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Retained Earnings vs Other Stockholder Equity
Retained Earnings vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiol Therapeutics Retained Earnings account and Other Stockholder Equity. At this time, the significance of the direction appears to have pay attention.
The correlation between Cardiol Therapeutics' Retained Earnings and Other Stockholder Equity is -0.95. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Cardiol Therapeutics Class, assuming nothing else is changed. The correlation between historical values of Cardiol Therapeutics' Retained Earnings and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Cardiol Therapeutics Class are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Retained Earnings i.e., Cardiol Therapeutics' Retained Earnings and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | -0.95 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Other Stockholder Equity
Most indicators from Cardiol Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. The value of Selling General Administrative is expected to slide to about 14.6 M. The value of Issuance Of Capital Stock is estimated to slide to about 39.4 M
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 220.4K | 219.9K | 195.3K | 182.4K | Interest Income | 106.0K | 1.2M | 2.2M | 2.3M |
Cardiol Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Cardiol Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardiol Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.5M | 15.9M | 87.9M | 62.0M | 36.7M | 38.6M | |
Short Long Term Debt Total | 190.8K | 156.6K | 117.6K | 72.9K | 174.3K | 133.9K | |
Other Current Liab | 640.1K | 696.1K | 7.4M | 1.4M | 655.0K | 622.2K | |
Total Current Liabilities | 690.5K | 2.5M | 11.6M | 9.8M | 8.3M | 5.5M | |
Total Stockholder Equity | 14.7M | 13.3M | 76.2M | 52.2M | 28.2M | 33.0M | |
Net Tangible Assets | 14.1M | 12.8M | 75.9M | 51.9M | 59.7M | 32.7M | |
Property Plant And Equipment Net | 584.0K | 479.6K | 356.5K | 295.7K | 337.1K | 329.6K | |
Net Debt | (6.8M) | (13.9M) | (83.8M) | (59.4M) | (34.8M) | (36.5M) | |
Retained Earnings | (31.2M) | (51.9M) | (83.5M) | (114.4M) | (142.6M) | (135.4M) | |
Accounts Payable | 561.3K | 1.8M | 4.1M | 8.3M | 7.6M | 3.9M | |
Cash | 7.0M | 14.0M | 83.9M | 59.5M | 34.9M | 34.3M | |
Non Current Assets Total | 1.1M | 943.2K | 735.7K | 590.5K | 547.4K | 610.6K | |
Cash And Short Term Investments | 7.0M | 14.0M | 83.9M | 59.5M | 34.9M | 34.3M | |
Net Receivables | 927.9K | 219.9K | 407.1K | 480.2K | 279.9K | 452.2K | |
Common Stock Shares Outstanding | 25.8M | 29.9M | 43.2M | 62.5M | 64.5M | 41.5M | |
Liabilities And Stockholders Equity | 15.5M | 15.9M | 87.9M | 62.0M | 36.7M | 38.6M | |
Non Current Liabilities Total | 140.3K | 104.7K | 72.9K | 22.4K | 158.5K | 109.5K | |
Other Stockholder Equity | 4.8M | 8.8M | 12.7M | 15.6M | 18.8M | 10.0M | |
Total Liab | 830.8K | 2.6M | 11.6M | 9.8M | 8.5M | 5.7M | |
Net Invested Capital | 14.7M | 13.3M | 76.2M | 52.2M | 60.0M | 33.4M | |
Total Current Assets | 14.4M | 14.9M | 87.1M | 61.4M | 36.2M | 37.8M | |
Net Working Capital | 13.7M | 12.4M | 75.6M | 51.6M | 59.4M | 32.5M | |
Intangible Assets | 548.1K | 463.7K | 379.2K | 294.8K | 210.4K | 371.0K | |
Common Stock | 39.4M | 51.9M | 142.9M | 147.5M | 148.5M | 89.8M | |
Property Plant Equipment | 584.0K | 479.6K | 356.5K | 295.7K | 340.1K | 322.7K | |
Inventory | 1.1M | 18.0K | 339.1K | (279.9K) | (251.9K) | (239.3K) | |
Other Current Assets | 5.4M | 347.8K | 2.8M | 1.5M | 1.2M | 1.6M | |
Capital Stock | 39.4M | 51.9M | 142.9M | 147.5M | 169.7M | 92.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.